For US Health Care Professionals Only

How EURAX® Is Supplied

EURAX is available in cream and lotion formulations2

Dosage Form Size NDC No.
Cream
Recommended for isolated areas
EURAX Cream 60-g tube 10631-091-60
Lotion
Recommended for widespread areas
EURAX Lotion 16-oz bottle
EURAX Lotion 2-oz bottle
10631-092-16
10631-092-60

IMPORTANT SAFETY INFORMATION
INDICATIONS AND USAGE: For eradication of scabies (Sarcoptes scabiei) and for symptomatic treatment of pruritic skin.

SUMMARY OF RISK INFORMATION FOR EURAX CREAM AND LOTION

CONTRAINDICATIONS: EURAX Cream or Lotion should not be applied topically to patients who develop sensitivity or are allergic to it or who manifest a primary irritation response to topical medications.

PRECAUTIONS: If severe irritation or sensitization develops, treatment with this product should be discontinued and appropriate therapy instituted.

EURAX Cream or Lotion should not be applied to the eyes or mouth because it may cause irritation. It should not be applied to acutely inflamed skin or raw or weeping surface until the acute inflammation has subsided.

It is not known whether EURAX Cream or Lotion can cause fetal harm when applied topically to a pregnant woman or if it affects reproduction capacity. EURAX Cream or Lotion should be given to a pregnant woman only if clearly needed.

Safety and effectiveness in pediatric patients have not been established.

Clinical studies with EURAX Cream or Lotion did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger patients.

ADVERSE REACTIONS: Primary irritation reactions such as dermatitis, pruritus, and rash, and allergic sensitivity reactions have been reported in a few patients.

This preparation is not for ophthalmic, oral, or intravaginal use.
For topical use only. Please see Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Reference: 2. Eurax [prescribing information]. Jacksonville, FL: Ranbaxy Laboratories Inc.; March 2009.
EURAX is a registered trademark of Ranbaxy Laboratories Inc.

Important Safety Information

IMPORTANT SAFETY INFORMATION
INDICATIONS AND USAGE: For eradication of scabies (Sarcoptes scabiei) and for symptomatic treatment of pruritic skin.

SUMMARY OF RISK INFORMATION FOR EURAX CREAM AND LOTION

CONTRAINDICATIONS: EURAX Cream or Lotion should not be applied topically to patients who develop sensitivity or are allergic to it or who manifest a primary irritation response to topical medications.

PRECAUTIONS: If severe irritation or sensitization develops, treatment with this product should be discontinued and appropriate therapy instituted.

EURAX Cream or Lotion should not be applied to the eyes or mouth because it may cause irritation. It should not be applied to acutely inflamed skin or raw or weeping surface until the acute inflammation has subsided.

It is not known whether EURAX Cream or Lotion can cause fetal harm when applied topically to a pregnant woman or if it affects reproduction capacity. EURAX Cream or Lotion should be given to a pregnant woman only if clearly needed.

Safety and effectiveness in pediatric patients have not been established.

Clinical studies with EURAX Cream or Lotion did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger patients.

ADVERSE REACTIONS: Primary irritation reactions such as dermatitis, pruritus, and rash, and allergic sensitivity reactions have been reported in a few patients.

This preparation is not for ophthalmic, oral, or intravaginal use.
For topical use only. Please see Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.